Drug Trial Radar · NCT05308225
Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Apr 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
72
Actual
Start
Feb 1, 2023
Primary completion
Dec 2025
Study completion Jul 2026
Sponsor
- Lead sponsor
- Sorrento Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a two-stage phase 1b/2a, open-label, multicenter, dose-escalation study of STI-6129 administered intravenously once in a 4-week cycle in subjects with relapsed or refractory multiple myeloma.
Conditions
- Multiple Myeloma
Interventions
STI-6129Biological
Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of STI-6129Time frame: Baseline through study completion at up to approximately 24 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
NYU Lagone Health
New York, New York
Columbia University Medical Center
New York, New York
Gabrail Cancer Center
Canton, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.